Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Metastatic Breast Cancer

Trial Name: A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treatment with Single Agent Tamoxifen.

Protocol ID: E3108

Eligibility:

 

Eligibility:

  • Must have estrogen and/or progesterone receptor positive histologically confirmed adenocarcinoma of the breast.
  • Age >18 yrs
  • Women must not be pregnant or breast-feeding due to harmful effects of tamoxifen.
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of non-hormonal contraception.
  • Patient must not have had chemotherapy or trastuzumab (Herceptin) for metastatic disease.  Chemotherapy or trastuzumab or bevacizumab in the adjuvant setting is allowed but must have been completed at least 6 weeks prior to study initiation.
  • Non-protocol concurrent hormonal therapy is not allowed.
  • Patient must meet required laboratory values.

Patient must be disease-free of prior invasive malignancies for >5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

Enrollment: • About 240 people will take part in this study at several medical centers.

Benefits:

By enrolling in this study there is no additional benefit to you.  We hope the information from this study will help doctors learn more about the proper use of tamoxifen as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Aug 17, 2011

Updated: Jan 18, 2013

« Return to Trials